respiratory syncytial virus (RSV)

February 23, 2018

Hope for an RSV vaccine

Newly discovered features in an RSV protein may be useful for rational structure-based vaccine design.

By Bill Snyder
May 15, 2017

RSV-HRV viral interference

RSV infection reduces the risk of infection with human rhinovirus, which could have implications for vaccine development and prevention strategies for viral respiratory tract infections in infants.

By Leigh MacMillan
February 9, 2017

Team isolates new antibodies that may aid RSV vaccine design

Researchers at Vanderbilt University Medical Center (VUMC) have taken another step toward developing a vaccine against respiratory syncytial virus (RSV), the major cause of life-threatening pneumonia in infants worldwide.

By Bill Snyder
knight with sword and shield
October 20, 2016

Research sheds light on how RSV wards off potential vaccines

Respiratory syncytial virus (RSV) is the major cause of life-threatening viral pneumonia in infants worldwide, yet despite repeated efforts, scientists have been unable to develop an effective vaccine against it.

By Bill Snyder
little girl using inhaler
July 21, 2016

Team to study RSV’s role in asthma formation

Investigators in the Division of Allergy, Pulmonary and Critical Care Medicine recently received a $4.5 million Asthma and Allergic Diseases Cooperative Research Center (AADCRC) grant from the National Institutes of Allergy and Infectious Diseases (NIAID).

By VUMC News and Communications
April 2, 2015

Gene variant, environment can boost RSV severity

A particular genetic mutation combined with an urban environment increases the risk of severe disease in children infected with respiratory syncytial virus (RSV), an international team of investigators has found.

By Leigh MacMillan
February 26, 2015

Respiratory viruses are main childhood pneumonia culprit: Study

Respiratory viruses, not bacterial infections, are the most commonly detected causes of community-acquired pneumonia in children, according to new research released Feb. 26 in the New England Journal of Medicine.
By Christina Echegaray
July 17, 2014

Study identifies antibody that may fight MPV, RSV

New Vanderbilt-led research published in the Journal of Infectious Diseases has identified an antibody that shows promise in preventing and treating human metapneumovirus (MPV) and respiratory syncytial virus (RSV) — the two leading causes of respiratory infections in young children.
By Christina Echegaray
February 5, 2014

Discovery may pave way for RSV vaccine

Vanderbilt University scientists have contributed to a major finding, reported this week in the journal Nature, which could lead to the first effective vaccine against respiratory syncytial virus (RSV), a significant cause of infant mortality.
By Bill Snyder
July 18, 2013

VU researchers ‘goldsmith’ new RSV vaccine approach

Vanderbilt vaccine researchers are using gold nanotechnology to develop a new approach to making vaccines.
By VUMC News and Communications
March 4, 2013

Study finds maternal diet may predict RSV severity

An important predictor of the severity of respiratory syncytial virus (RSV) in infants may be what their mothers ate during pregnancy.
By VUMC News and Communications
September 25, 2012

Cell entry ports for cold virus

The respiratory virus HMPV uses its fusion (F) protein – which interacts with cellular receptors called integrins – to bind to and enter target cells.
By Leigh MacMillan
August 9, 2012

New therapeutic target for cold, flu viruses identified

Viruses that cause acute respiratory infections — such as human metapneumovirus (HMPV) and flu — impair a set of immune system cells that should clear the virus from the lungs. Now, Vanderbilt University investigators have discovered the signaling pathway that disables these immune cells.
By Leigh MacMillan
1 2 3